Profile: VDM Biochemicals, Inc. offers life science products which are focused on all areas of cancer research, apoptosis, antivirals, antibiotics, enzyme inhibitors, anticoagulants, cannabinoids, cholinergics, histaminergics, intermediates and fine chemicals. Cell-permeable hydroxystryrylacrylonitrile tyrosine kinase inhibitor displays anti-tumor properties. Potently inhibits the kinase activities of JAK2 & Bcr-Abl (IC50 ~100-600 nM and 500-700 nM, respectively), and displays selectivity over other tyrosine kinases, Btk, Lck, Lyn, Src, Syk & ZAP-70 (IC50>5 M). Its in vivo efficacy in cancer reduction which has been successfully demonstrated in NOD-SCID mice engrafted with human Ph+ ALL cells. AM-251 is a 123I radioisotope derivative of the CB1 cannabinoid receptor inverse agonist SR141716A, presenting a radioprobe for in vivo binding studies at the CB1 receptor with a higher affinity (Ki = 7.49 nM) for CB1 than the parent compound (Ki = 11.5 nM). AM-251 has been employed in competitive binding studies to identify CB1 affinity of different cannabimimetic agonists in vivo. Characterization of AM-251-CB1 association with SPECT (single photon emission computed tomography) which has been described.